Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53

Summary Differentiated thyroid carcinomas (in contrast to the rarer anaplastic form) are unusual among human cancers in displaying a remarkably low frequency of p53 mutation and appear to retain wild-type (wt) p53 function as assessed by the response of derived cell lines to DNA damage. Using one su...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 1999-03, Vol.79 (7), p.1111-1120
Hauptverfasser: Wyllie, F S, Haughton, M F, Rowson, J M, Wynford-Thomas, D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1120
container_issue 7
container_start_page 1111
container_title British journal of cancer
container_volume 79
creator Wyllie, F S
Haughton, M F
Rowson, J M
Wynford-Thomas, D
description Summary Differentiated thyroid carcinomas (in contrast to the rarer anaplastic form) are unusual among human cancers in displaying a remarkably low frequency of p53 mutation and appear to retain wild-type (wt) p53 function as assessed by the response of derived cell lines to DNA damage. Using one such cell line, K1, we have tested the effect of experimental abrogation of p53 function by generating matched sub-clones stably expressing either a neo control gene, a dominant-negative mutant p53 (143 ala ) or human papilloma virus protein HPV16 E6. Loss of p53 function in the latter two groups was confirmed by abolition of p53-dependent ‘stress’ responses including induction of the cyclin/CDK inhibitor p21WAF1 and G1/S arrest following DNA-damage. In contrast, no change was detected in the phenotype of ‘unstressed’ clones, with respect to any of the following parameters: proliferation rate in monolayer, serum-dependence for proliferation or survival, tumorigenicity, cellular morphology, or tissue-specific differentiation markers. The K1 line therefore represents a ‘neutral’ background with respect to p53 function, permitting the derivation of functionally p53 + or – clones which are not only iso-genic but also iso-phenotypic. Such a panel should be an ideal tool with which to test the p53-dependence of cellular stress responses, particularly the sensitivity to potential therapeutic agents, free from the confounding additional phenotypic differences which usually accompany loss of p53 function. The results also further support the hypothesis that p53 mutation alone is not sufficient to drive progression of thyroid cancer to the aggressive anaplastic form.
doi_str_mv 10.1038/sj.bjc.6690177
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17228212</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-938fb89f937916eba547450e7d58b78993394a3bf5d257b40334ff313b528dae3</originalsourceid><addsrcrecordid>eNqFkc-L1DAUgIMo7uzq1aPkIJ7sbH42yUWQRXeFBS96DmmazKS0SU1aZf57szODrgcRAu-F9-UlLx8ArzDaYkTldRm23WC3basQFuIJ2GBOSYMlEU_BBiEkGqQIugCXpQx1q5AUz8EFrpkUjG3AdLdOJsJlf8gp9NCaaF2G1o1jgaYuWNKarYPJw1BSs3Mx2HfHdN67mJbDHOwRh2OIrsCfYdnDlI8xrQv0a7RLSNGMcOb0BXjmzVjcy3O8At8-ffx6c9fcf7n9fPPhvrFMtkujqPSdVF5RoXDrOsOZYBw50XPZCakUpYoZ2nneEy46hihl3lNMO05kbxy9Au9Pfee1m1xvXVyyGfWcw2TyQScT9N-VGPZ6l35oQltCiKgN3p4b5PR9dWXRUygPY5ro0lp0q1rOJOP_BbEgRBJMKrg9gTanUrLzv1-DkX5Qqcugq0p9VlkPvH48wyP85K4Cb86AKdaMPld3ofzhWlk_E1fs-oSVWok7l_VQlVYh5V83_wLsZbh_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17228212</pqid></control><display><type>article</type><title>Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wyllie, F S ; Haughton, M F ; Rowson, J M ; Wynford-Thomas, D</creator><creatorcontrib>Wyllie, F S ; Haughton, M F ; Rowson, J M ; Wynford-Thomas, D</creatorcontrib><description>Summary Differentiated thyroid carcinomas (in contrast to the rarer anaplastic form) are unusual among human cancers in displaying a remarkably low frequency of p53 mutation and appear to retain wild-type (wt) p53 function as assessed by the response of derived cell lines to DNA damage. Using one such cell line, K1, we have tested the effect of experimental abrogation of p53 function by generating matched sub-clones stably expressing either a neo control gene, a dominant-negative mutant p53 (143 ala ) or human papilloma virus protein HPV16 E6. Loss of p53 function in the latter two groups was confirmed by abolition of p53-dependent ‘stress’ responses including induction of the cyclin/CDK inhibitor p21WAF1 and G1/S arrest following DNA-damage. In contrast, no change was detected in the phenotype of ‘unstressed’ clones, with respect to any of the following parameters: proliferation rate in monolayer, serum-dependence for proliferation or survival, tumorigenicity, cellular morphology, or tissue-specific differentiation markers. The K1 line therefore represents a ‘neutral’ background with respect to p53 function, permitting the derivation of functionally p53 + or – clones which are not only iso-genic but also iso-phenotypic. Such a panel should be an ideal tool with which to test the p53-dependence of cellular stress responses, particularly the sensitivity to potential therapeutic agents, free from the confounding additional phenotypic differences which usually accompany loss of p53 function. The results also further support the hypothesis that p53 mutation alone is not sufficient to drive progression of thyroid cancer to the aggressive anaplastic form.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6690177</identifier><identifier>PMID: 10098744</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma, Papillary - genetics ; Carcinoma, Papillary - metabolism ; Carcinoma, Papillary - pathology ; Cell Count ; Cell Differentiation ; DNA-Binding Proteins - metabolism ; Drug Resistance ; Endocrinopathies ; Epidemiology ; G1 Phase - genetics ; G2 Phase - genetics ; Gene Deletion ; Genes, p53 - genetics ; Genetic Vectors - administration &amp; dosage ; Genotype ; Humans ; Malignant tumors ; Medical sciences ; Molecular Medicine ; Nuclear Proteins ; Oncogene Proteins, Viral - metabolism ; Oncology ; Paired Box Transcription Factors ; PAX8 Transcription Factor ; Phenotype ; Regular ; regular-article ; Repressor Proteins ; Thyroid Neoplasms - genetics ; Thyroid Neoplasms - metabolism ; Thyroid Neoplasms - pathology ; Thyroid. Thyroid axis (diseases) ; Time Factors ; Trans-Activators - metabolism ; Transfection ; Tumor Cells, Cultured - metabolism ; Tumor Cells, Cultured - pathology ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>British journal of cancer, 1999-03, Vol.79 (7), p.1111-1120</ispartof><rights>The Author(s) 1999</rights><rights>1999 INIST-CNRS</rights><rights>Copyright © 1999 Cancer Research Campaign 1999 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-938fb89f937916eba547450e7d58b78993394a3bf5d257b40334ff313b528dae3</citedby><cites>FETCH-LOGICAL-c486t-938fb89f937916eba547450e7d58b78993394a3bf5d257b40334ff313b528dae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362227/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362227/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51298,53770,53772</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1684861$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10098744$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wyllie, F S</creatorcontrib><creatorcontrib>Haughton, M F</creatorcontrib><creatorcontrib>Rowson, J M</creatorcontrib><creatorcontrib>Wynford-Thomas, D</creatorcontrib><title>Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Summary Differentiated thyroid carcinomas (in contrast to the rarer anaplastic form) are unusual among human cancers in displaying a remarkably low frequency of p53 mutation and appear to retain wild-type (wt) p53 function as assessed by the response of derived cell lines to DNA damage. Using one such cell line, K1, we have tested the effect of experimental abrogation of p53 function by generating matched sub-clones stably expressing either a neo control gene, a dominant-negative mutant p53 (143 ala ) or human papilloma virus protein HPV16 E6. Loss of p53 function in the latter two groups was confirmed by abolition of p53-dependent ‘stress’ responses including induction of the cyclin/CDK inhibitor p21WAF1 and G1/S arrest following DNA-damage. In contrast, no change was detected in the phenotype of ‘unstressed’ clones, with respect to any of the following parameters: proliferation rate in monolayer, serum-dependence for proliferation or survival, tumorigenicity, cellular morphology, or tissue-specific differentiation markers. The K1 line therefore represents a ‘neutral’ background with respect to p53 function, permitting the derivation of functionally p53 + or – clones which are not only iso-genic but also iso-phenotypic. Such a panel should be an ideal tool with which to test the p53-dependence of cellular stress responses, particularly the sensitivity to potential therapeutic agents, free from the confounding additional phenotypic differences which usually accompany loss of p53 function. The results also further support the hypothesis that p53 mutation alone is not sufficient to drive progression of thyroid cancer to the aggressive anaplastic form.</description><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma, Papillary - genetics</subject><subject>Carcinoma, Papillary - metabolism</subject><subject>Carcinoma, Papillary - pathology</subject><subject>Cell Count</subject><subject>Cell Differentiation</subject><subject>DNA-Binding Proteins - metabolism</subject><subject>Drug Resistance</subject><subject>Endocrinopathies</subject><subject>Epidemiology</subject><subject>G1 Phase - genetics</subject><subject>G2 Phase - genetics</subject><subject>Gene Deletion</subject><subject>Genes, p53 - genetics</subject><subject>Genetic Vectors - administration &amp; dosage</subject><subject>Genotype</subject><subject>Humans</subject><subject>Malignant tumors</subject><subject>Medical sciences</subject><subject>Molecular Medicine</subject><subject>Nuclear Proteins</subject><subject>Oncogene Proteins, Viral - metabolism</subject><subject>Oncology</subject><subject>Paired Box Transcription Factors</subject><subject>PAX8 Transcription Factor</subject><subject>Phenotype</subject><subject>Regular</subject><subject>regular-article</subject><subject>Repressor Proteins</subject><subject>Thyroid Neoplasms - genetics</subject><subject>Thyroid Neoplasms - metabolism</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid. Thyroid axis (diseases)</subject><subject>Time Factors</subject><subject>Trans-Activators - metabolism</subject><subject>Transfection</subject><subject>Tumor Cells, Cultured - metabolism</subject><subject>Tumor Cells, Cultured - pathology</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNqFkc-L1DAUgIMo7uzq1aPkIJ7sbH42yUWQRXeFBS96DmmazKS0SU1aZf57szODrgcRAu-F9-UlLx8ArzDaYkTldRm23WC3basQFuIJ2GBOSYMlEU_BBiEkGqQIugCXpQx1q5AUz8EFrpkUjG3AdLdOJsJlf8gp9NCaaF2G1o1jgaYuWNKarYPJw1BSs3Mx2HfHdN67mJbDHOwRh2OIrsCfYdnDlI8xrQv0a7RLSNGMcOb0BXjmzVjcy3O8At8-ffx6c9fcf7n9fPPhvrFMtkujqPSdVF5RoXDrOsOZYBw50XPZCakUpYoZ2nneEy46hihl3lNMO05kbxy9Au9Pfee1m1xvXVyyGfWcw2TyQScT9N-VGPZ6l35oQltCiKgN3p4b5PR9dWXRUygPY5ro0lp0q1rOJOP_BbEgRBJMKrg9gTanUrLzv1-DkX5Qqcugq0p9VlkPvH48wyP85K4Cb86AKdaMPld3ofzhWlk_E1fs-oSVWok7l_VQlVYh5V83_wLsZbh_</recordid><startdate>19990301</startdate><enddate>19990301</enddate><creator>Wyllie, F S</creator><creator>Haughton, M F</creator><creator>Rowson, J M</creator><creator>Wynford-Thomas, D</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19990301</creationdate><title>Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53</title><author>Wyllie, F S ; Haughton, M F ; Rowson, J M ; Wynford-Thomas, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-938fb89f937916eba547450e7d58b78993394a3bf5d257b40334ff313b528dae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma, Papillary - genetics</topic><topic>Carcinoma, Papillary - metabolism</topic><topic>Carcinoma, Papillary - pathology</topic><topic>Cell Count</topic><topic>Cell Differentiation</topic><topic>DNA-Binding Proteins - metabolism</topic><topic>Drug Resistance</topic><topic>Endocrinopathies</topic><topic>Epidemiology</topic><topic>G1 Phase - genetics</topic><topic>G2 Phase - genetics</topic><topic>Gene Deletion</topic><topic>Genes, p53 - genetics</topic><topic>Genetic Vectors - administration &amp; dosage</topic><topic>Genotype</topic><topic>Humans</topic><topic>Malignant tumors</topic><topic>Medical sciences</topic><topic>Molecular Medicine</topic><topic>Nuclear Proteins</topic><topic>Oncogene Proteins, Viral - metabolism</topic><topic>Oncology</topic><topic>Paired Box Transcription Factors</topic><topic>PAX8 Transcription Factor</topic><topic>Phenotype</topic><topic>Regular</topic><topic>regular-article</topic><topic>Repressor Proteins</topic><topic>Thyroid Neoplasms - genetics</topic><topic>Thyroid Neoplasms - metabolism</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid. Thyroid axis (diseases)</topic><topic>Time Factors</topic><topic>Trans-Activators - metabolism</topic><topic>Transfection</topic><topic>Tumor Cells, Cultured - metabolism</topic><topic>Tumor Cells, Cultured - pathology</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wyllie, F S</creatorcontrib><creatorcontrib>Haughton, M F</creatorcontrib><creatorcontrib>Rowson, J M</creatorcontrib><creatorcontrib>Wynford-Thomas, D</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wyllie, F S</au><au>Haughton, M F</au><au>Rowson, J M</au><au>Wynford-Thomas, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1999-03-01</date><risdate>1999</risdate><volume>79</volume><issue>7</issue><spage>1111</spage><epage>1120</epage><pages>1111-1120</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Summary Differentiated thyroid carcinomas (in contrast to the rarer anaplastic form) are unusual among human cancers in displaying a remarkably low frequency of p53 mutation and appear to retain wild-type (wt) p53 function as assessed by the response of derived cell lines to DNA damage. Using one such cell line, K1, we have tested the effect of experimental abrogation of p53 function by generating matched sub-clones stably expressing either a neo control gene, a dominant-negative mutant p53 (143 ala ) or human papilloma virus protein HPV16 E6. Loss of p53 function in the latter two groups was confirmed by abolition of p53-dependent ‘stress’ responses including induction of the cyclin/CDK inhibitor p21WAF1 and G1/S arrest following DNA-damage. In contrast, no change was detected in the phenotype of ‘unstressed’ clones, with respect to any of the following parameters: proliferation rate in monolayer, serum-dependence for proliferation or survival, tumorigenicity, cellular morphology, or tissue-specific differentiation markers. The K1 line therefore represents a ‘neutral’ background with respect to p53 function, permitting the derivation of functionally p53 + or – clones which are not only iso-genic but also iso-phenotypic. Such a panel should be an ideal tool with which to test the p53-dependence of cellular stress responses, particularly the sensitivity to potential therapeutic agents, free from the confounding additional phenotypic differences which usually accompany loss of p53 function. The results also further support the hypothesis that p53 mutation alone is not sufficient to drive progression of thyroid cancer to the aggressive anaplastic form.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>10098744</pmid><doi>10.1038/sj.bjc.6690177</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 1999-03, Vol.79 (7), p.1111-1120
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362227
source MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
Carcinoma, Papillary - genetics
Carcinoma, Papillary - metabolism
Carcinoma, Papillary - pathology
Cell Count
Cell Differentiation
DNA-Binding Proteins - metabolism
Drug Resistance
Endocrinopathies
Epidemiology
G1 Phase - genetics
G2 Phase - genetics
Gene Deletion
Genes, p53 - genetics
Genetic Vectors - administration & dosage
Genotype
Humans
Malignant tumors
Medical sciences
Molecular Medicine
Nuclear Proteins
Oncogene Proteins, Viral - metabolism
Oncology
Paired Box Transcription Factors
PAX8 Transcription Factor
Phenotype
Regular
regular-article
Repressor Proteins
Thyroid Neoplasms - genetics
Thyroid Neoplasms - metabolism
Thyroid Neoplasms - pathology
Thyroid. Thyroid axis (diseases)
Time Factors
Trans-Activators - metabolism
Transfection
Tumor Cells, Cultured - metabolism
Tumor Cells, Cultured - pathology
Tumor Suppressor Protein p53 - metabolism
title Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T17%3A53%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20thyroid%20cancer%20cells%20as%20a%20source%20of%20iso-genic,%20iso-phenotypic%20cell%20lines%20with%20or%20without%20functional%20p53&rft.jtitle=British%20journal%20of%20cancer&rft.au=Wyllie,%20F%20S&rft.date=1999-03-01&rft.volume=79&rft.issue=7&rft.spage=1111&rft.epage=1120&rft.pages=1111-1120&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6690177&rft_dat=%3Cproquest_pubme%3E17228212%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17228212&rft_id=info:pmid/10098744&rfr_iscdi=true